List of Excipients in Branded Drug CANGRELOR
Generic Drugs Containing CANGRELOR
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Gland Pharma Limited | cangrelor | 68083-412 | MANNITOL |
| Gland Pharma Limited | cangrelor | 68083-412 | SODIUM HYDROXIDE |
| Gland Pharma Limited | cangrelor | 68083-412 | SORBITOL |
| >Company | >Ingredient | >NDC | >Excipient |
What are the Most Frequently-Used Excipients in CANGRELOR?
| # Of NDCs | Excipient |
|---|---|
| 1 | MANNITOL |
| 1 | SODIUM HYDROXIDE |
| 1 | SORBITOL |
| ># Of NDCs | >Excipient |
Cangrelor Excipient Strategy and Commercial Opportunities
Cangrelor is an intravenous, reversible P2Y12 platelet inhibitor used during percutaneous coronary intervention (PCI). The leading commercial opportunity is a lower-complexity sterile injectable that improves preparation time, dilution accuracy, stability, and hospital inventory economics. The current product, Kengreal, is supplied as a lyophilized 50 mg vial requiring reconstitution and further dilution before administration. Its excipient platform is comparatively simple, creating limited composition-of-matter differentiation but meaningful opportunities in presentation, packaging, manufacturing, and ready-to-administer delivery [1].
What is cangrelor and how is it administered?
Cangrelor is an ATP analog that produces rapid, reversible inhibition of the platelet P2Y12 receptor. It is administered intravenously as a bolus followed by continuous infusion during PCI when oral P2Y12 therapy is not suitable or cannot be absorbed reliably [1].
| Parameter | Current labeled information |
|---|---|
| Active ingredient | Cangrelor |
| Product | Kengreal |
| Dosage form | Lyophilized powder for intravenous solution |
| Vial strength | 50 mg |
| PCI bolus | 30 mcg/kg |
| Continuous infusion | 4 mcg/kg/min |
| Reconstitution | Sterile Water for Injection |
| Further dilution | 0.9% Sodium Chloride Injection or 5% Dextrose Injection |
| Administration | Intravenous bolus followed by infusion |
| Pharmacology | Rapid onset and offset; reversible platelet inhibition |
| FDA approval | June 22, 2015 |
| Primary use | Adjunctive antiplatelet therapy during PCI |
A 70 kg patient receives an initial bolus of approximately 2.1 mg, followed by an infusion of approximately 280 mcg per minute. The low dose relative to vial content makes residual drug, preparation losses, and pharmacy workflow important commercial factors.
Cangrelor has a short pharmacodynamic duration. Platelet function begins to recover within approximately one hour after discontinuation, although the exact clinical transition to oral therapy depends on the selected P2Y12 inhibitor and timing [1].
What excipients are used in the cangrelor formulation?
The commercial lyophilized formulation contains cangrelor tetrasodium and mannitol. The product is reconstituted with Sterile Water for Injection and then diluted for infusion in compatible intravenous fluids [1].
Functional role of mannitol
Mannitol is likely used as a bulking agent and lyophilization aid. In a low-dose injectable formulation, the active pharmaceutical ingredient alone may not provide adequate cake structure or mass for reliable vial filling and freeze-drying. Mannitol can improve:
- Lyophilized cake formation
- Vial-to-vial dose uniformity
- Reconstitution behavior
- Manufacturing handling
- Visual inspection of the dried product
Mannitol also affects the solid-state characteristics of the formulation. A generic manufacturer would need to control the crystalline form, residual moisture, cake appearance, reconstitution time, and post-reconstitution stability.
The commercial formulation does not depend on a complex surfactant, lipid, polymer, or preservative system. That reduces excipient-related regulatory risk but also limits the ability to create a strong composition-based patent position.
What formulation patents could protect cangrelor products?
Cangrelor formulation protection would likely focus on pharmaceutical compositions, lyophilization conditions, stability, reconstitution, container closure, and ready-to-use presentations rather than on a novel excipient alone.
Potential claim categories include:
| Patent category | Potential commercial subject matter | Relative value |
|---|---|---|
| Lyophilized composition | Cangrelor with mannitol and defined moisture or pH limits | Moderate |
| Reconstitution formulation | Defined concentration, diluent, pH, or reconstitution time | Moderate |
| Stability claims | Stability after reconstitution or dilution for a defined period | High if clinically useful |
| Ready-to-use product | Premixed solution or pharmacy-ready bag | High |
| Container closure | Low-sorption vial, syringe, or infusion bag | Moderate |
| Manufacturing process | Freeze-drying cycle, sterile filtration, or aseptic filling | Moderate |
| Administration system | Drug-device combination or closed transfer system | Moderate to high |
| Method of use | Timing with oral ticagrelor, clopidogrel, or prasugrel | Potentially limited by prior art |
A composition claim limited to cangrelor and mannitol would face vulnerability if the ingredients and their functions are disclosed in the reference product or prior patent literature. Stronger protection would usually require a technically meaningful limitation, such as an unexpected stability result, defined reconstitution performance, reduced aggregation, improved recovery, or a clinically relevant ready-to-administer format.
What commercial formulation opportunities exist for cangrelor?
The most credible opportunities are workflow products rather than new pharmacology.
Ready-to-use infusion bags
A premixed infusion bag could eliminate pharmacy reconstitution and reduce preparation errors. The main technical issues are:
- Chemical stability over the labeled shelf life
- Compatibility with bag materials
- Adsorption to tubing and infusion components
- Sterility assurance
- Concentration uniformity
- Temperature and light exposure
- Shipping and storage conditions
A premixed presentation could be positioned for high-volume catheterization laboratories and hospitals that use cangrelor during urgent or complex PCI.
Pharmacy-prepared dual-container systems
A dual-chamber vial, dual-chamber bag, or transfer-device system could separate the dry product from the diluent until use. This would preserve the current lyophilized stability advantage while reducing preparation steps.
The commercial value would be strongest if the system:
- Preserves the existing 50 mg dose.
- Uses standard hospital infusion equipment.
- Reduces calculation and dilution requirements.
- Provides clear activation and storage instructions.
- Maintains compatibility with automated pharmacy workflows.
Smaller or higher-concentration presentations
The current 50 mg vial may create substantial unused product depending on patient weight, treatment duration, and preparation volume. A smaller vial could reduce waste but would increase manufacturing, packaging, and inventory complexity.
A higher-concentration product could lower infusion volume, but the strategy would need to address dose calculation, pump accuracy, local tolerability, and compatibility. Since cangrelor is used in an acute-care setting, a higher concentration would need a clear operational advantage.
Stabilized liquid formulations
A liquid formulation could remove reconstitution steps, but it would face more demanding stability requirements than the lyophilized product. Key development risks include degradation in aqueous solution, pH sensitivity, container interactions, and stability after dilution.
A liquid product would have the greatest value if it could support:
- Longer refrigerated or room-temperature shelf life
- Direct connection to an infusion pump
- Reduced preparation time
- Fewer pharmacy manipulations
- Reliable use in emergency PCI
How strong is the patent estate for cangrelor?
Cangrelor’s commercial exclusivity profile is more vulnerable to generic competition than products with a long-lived composition-of-matter patent and multiple formulation patents.
Cangrelor was approved in 2015. The standard five-year new chemical entity exclusivity period would have expired in 2020, subject to any applicable pediatric extension or other FDA-recognized exclusivity [2]. The principal remaining barriers therefore depend on issued patents, Orange Book listings, patent-term adjustments, formulation claims, manufacturing claims, and regulatory litigation.
The patent estate should be separated into four layers:
| Estate layer | Relevance to cangrelor |
|---|---|
| Active ingredient patents | Potentially limited if expired or near expiry |
| Formulation patents | Relevant to lyophilized, liquid, or ready-to-use products |
| Method-of-use patents | May cover PCI dosing or transition to oral therapy |
| Process and device patents | Can delay or differentiate commercial entry without blocking all generic formulations |
Patent strength is highest when claims cover a formulation characteristic that is difficult to design around and necessary for an FDA-approved product. It is weaker when claims cover routine excipient selection, conventional freeze-drying, or broad clinical use concepts already described in the label or prior art.
Current Orange Book listings, patent expiration dates, and any patent-term adjustments must be verified against the FDA’s current Orange Book and Drugs@FDA records before investment, licensing, or litigation decisions [2,3]. A static patent summary can become inaccurate after patent expiry, terminal disclaimers, delisting, or court proceedings.
When does cangrelor lose exclusivity and face generic entry?
The core regulatory exclusivity period has already expired. A generic applicant would generally pursue an abbreviated new drug application (ANDA), provided it can demonstrate pharmaceutical equivalence and bioequivalence or satisfy FDA’s applicable waiver or alternative requirements for the injectable product [4].
The principal generic-entry scenarios are:
| Scenario | Product approach | Commercial effect |
|---|---|---|
| Conventional generic vial | Lyophilized cangrelor with reconstitution | Most direct competition |
| Alternate excipient formulation | Same active ingredient with different inactive ingredients | Requires compatibility and safety justification |
| Ready-to-use product | Premixed liquid or bag | Could compete on workflow rather than price |
| Device-enabled product | Transfer system or integrated delivery format | May create differentiated hospital value |
| 505(b)(2) product | Reformulated or new presentation product | More relevant to novel delivery systems than a conventional generic |
A Paragraph IV challenge would be relevant only to an unexpired Orange Book-listed patent. It would not challenge FDA exclusivity that has already expired. The commercial impact would depend on whether the reference-product sponsor sues within the statutory period, whether a 30-month stay applies, and whether the challenged claims survive litigation [4,5].
What is the FDA regulatory status of cangrelor?
Kengreal is an FDA-approved prescription drug for use during PCI. It is not a biologic, so biosimilar competition does not apply. The relevant follow-on pathway is generic competition under section 505(j) or, for certain reformulated products, a 505(b)(2) application [1,4].
Regulatory review would focus on:
- Identity and strength of cangrelor
- Sterility and particulate control
- Reconstitution and dilution performance
- Stability and degradation products
- Compatibility with approved diluents
- Container-closure integrity
- Extractables and leachables
- Dose delivery through infusion systems
- Labeling for bolus and continuous infusion
For a conventional injectable generic, a different excipient system may be acceptable, but it can trigger additional safety and compatibility scrutiny. A formulation that changes pH, osmolality, reconstitution time, or infusion compatibility could increase development risk.
What manufacturing and IP barriers affect cangrelor?
Cangrelor is a sterile injectable with a short clinical workflow and low dose relative to vial size. Manufacturing barriers include:
- Consistent sterile filling of a low-dose active
- Freeze-drying cycle control
- Residual-moisture management
- Recovery of cangrelor after reconstitution
- Control of degradation during dilution
- Compatibility with infusion bags and tubing
- Reliable supply of pharmaceutical-grade mannitol
- Aseptic manufacturing capacity
The most defensible manufacturing IP would relate to process parameters that produce a measurable product advantage. Examples include improved reconstitution time, reduced degradation, increased recovery from the vial, or enhanced stability in a commercially useful container.
A process patent may not block a generic manufacturer if an alternative process can produce an equivalent product. Its value is therefore highest when the process is closely tied to the required quality attributes and difficult to reproduce economically.
Which companies are positioned to challenge or compete with cangrelor?
Competition is likely to come from three groups:
- Generic injectable manufacturers seeking to launch a conventional cangrelor vial.
- Specialty injectable companies developing premixed or pharmacy-ready presentations.
- Hospital-supply and drug-device companies offering preparation or administration systems.
The competitive threat is not limited to a lower-priced vial. Hospitals may value reduced compounding time, lower medication-error risk, lower waste, and improved operating-room or catheterization-laboratory throughput.
Cangrelor also competes clinically with oral P2Y12 inhibitors, including clopidogrel, prasugrel, and ticagrelor. Those products are not direct substitutes in every patient because cangrelor is used when immediate intravenous platelet inhibition is needed or oral absorption is unreliable. Their availability and price can nevertheless constrain cangrelor utilization [1].
What licensing and partnership opportunities exist?
The strongest licensing opportunities are likely to involve formulation and delivery technology rather than the cangrelor molecule itself.
Potential transactions include:
- Licensing a premixed liquid formulation
- Contract development of a stable infusion bag
- Acquiring a sterile injectable manufacturing platform
- Partnering with a catheterization-laboratory supplier
- Licensing a closed transfer or reconstitution device
- Regional commercialization rights for a generic or authorized generic
- Supply agreements for pharmaceutical-grade mannitol and container systems
An asset owner would need to show more than a new excipient combination. Commercially meaningful diligence would focus on stability data, preparation-time reduction, waste reduction, manufacturing cost, regulatory pathway, and freedom to operate against formulation and device patents.
What revenue exposure and generic launch risks exist?
Cangrelor revenue is exposed to rapid generic erosion because the product is an acute-care injectable with limited patient-level brand loyalty. Hospitals and group purchasing organizations typically place significant weight on price, supply continuity, contract terms, and operational convenience.
Generic launch risk is highest when:
- No blocking patent remains enforceable.
- The reference product has no exclusive device presentation.
- A conventional vial can be manufactured by multiple suppliers.
- Hospital protocols allow substitution.
- The product has a simple excipient profile.
- The market has excess sterile injectable capacity.
Revenue erosion may be slower if the branded product has a strong supply record, favorable hospital contracts, bundled offerings, or a differentiated ready-to-use presentation. A premixed product could also preserve price through workflow savings even after conventional vial competition begins.
Key Takeaways
- Cangrelor’s current formulation is a relatively simple lyophilized sterile injectable containing cangrelor tetrasodium and mannitol.
- The highest-value excipient strategy is tied to stability, reconstitution, and ready-to-administer delivery.
- A conventional generic vial is the most direct competitive threat after expiration of applicable patent barriers.
- Biosimilar competition does not apply because cangrelor is a small-molecule drug.
- The five-year new chemical entity exclusivity period associated with the 2015 FDA approval has expired.
- Premixed bags, dual-chamber systems, smaller vials, and pharmacy-ready formats offer the clearest commercial opportunities.
- Formulation patents are strongest when they claim measurable stability, recovery, or workflow advantages rather than routine excipient selection.
- Current Orange Book listings, patent expiry dates, and litigation activity control the final launch-risk assessment.
FAQs
Can mannitol be replaced in a generic cangrelor formulation?
Yes. A generic manufacturer may use a different excipient system if the product satisfies FDA requirements for pharmaceutical equivalence, stability, sterility, safety, and performance. Replacing mannitol could alter cake structure, reconstitution, moisture, and degradation behavior.
Is a ready-to-use cangrelor infusion eligible for an ANDA?
Not necessarily. A materially different presentation, concentration, formulation, or delivery system may require a 505(b)(2) application rather than a conventional ANDA. The regulatory classification depends on the extent of difference from the reference product.
Does cangrelor have biosimilar risk?
No. Cangrelor is a small-molecule drug. Follow-on competition would arise through an ANDA or, for certain reformulated products, a 505(b)(2) application.
What excipient creates the most formulation opportunity for cangrelor?
The primary opportunity is not a single excipient. It is a formulation system that improves liquid stability, reduces adsorption, accelerates reconstitution, or supports a premixed product. Mannitol is established as a lyophilization and bulking excipient, which may limit its standalone patent value.
Can a cangrelor manufacturer obtain new patents after the original exclusivity period?
Yes. New patents may cover a novel formulation, stable liquid presentation, container system, manufacturing process, delivery device, or specific method of use. Such patents must satisfy novelty, non-obviousness, written-description, enablement, and claim-scope requirements.
References
-
U.S. Food and Drug Administration. (2024). Kengreal (cangrelor) for injection: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (2014). ANDA submissions: Refuse-to-receive standards. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
ISSN: 2162-2639

Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Access the Complete Database
BioPharmaceutical Business Intelligence
- Analyze global market entry opportunities
- Uncover prior art in expired and abandoned patents
- Obtain formulation and manufacturing information